OTCMKTS:SEOVF

Sernova Competitors

$1.16
+0.01 (+0.87 %)
(As of 04/20/2021 05:19 PM ET)
Add
Compare
Today's Range
$1.14
Now: $1.16
$1.20
50-Day Range
$0.98
MA: $1.17
$1.34
52-Week Range
$0.10
Now: $1.16
$2.23
Volume45,199 shs
Average Volume148,531 shs
Market Capitalization$299.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46

Competitors

Sernova (OTCMKTS:SEOVF) Vs. OCUL, CDMO, PTGX, YMAB, PHAT, and KRON

Should you be buying SEOVF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Sernova, including Ocular Therapeutix (OCUL), Avid Bioservices (CDMO), Protagonist Therapeutics (PTGX), Y-mAbs Therapeutics (YMAB), Phathom Pharmaceuticals (PHAT), and Kronos Bio (KRON).

Ocular Therapeutix (NASDAQ:OCUL) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
SernovaN/A-195.56%-151.94%

Institutional and Insider Ownership

52.5% of Ocular Therapeutix shares are owned by institutional investors. 7.7% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Ocular Therapeutix and Sernova's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million265.80$-86,370,000.00($2.01)-7.35
SernovaN/AN/A$-2,990,000.00N/AN/A

Sernova has lower revenue, but higher earnings than Ocular Therapeutix.

Analyst Recommendations

This is a summary of current ratings and price targets for Ocular Therapeutix and Sernova, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Sernova0000N/A

Ocular Therapeutix presently has a consensus target price of $24.80, indicating a potential upside of 67.79%. Given Ocular Therapeutix's higher probable upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Sernova.

Summary

Ocular Therapeutix beats Sernova on 9 of the 12 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMO) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Profitability

This table compares Avid Bioservices and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid Bioservices0.20%0.31%0.13%
SernovaN/A-195.56%-151.94%

Earnings & Valuation

This table compares Avid Bioservices and Sernova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid Bioservices$59.70 million19.37$-10,470,000.00($0.27)-70.41
SernovaN/AN/A$-2,990,000.00N/AN/A

Sernova has lower revenue, but higher earnings than Avid Bioservices.

Institutional & Insider Ownership

58.2% of Avid Bioservices shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Avid Bioservices and Sernova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices00303.00
Sernova0000N/A

Avid Bioservices presently has a consensus target price of $17.3333, indicating a potential downside of 8.82%. Given Avid Bioservices' higher probable upside, analysts clearly believe Avid Bioservices is more favorable than Sernova.

Volatility & Risk

Avid Bioservices has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Summary

Avid Bioservices beats Sernova on 9 of the 11 factors compared between the two stocks.

Sernova (OTCMKTS:SEOVF) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Sernova and Protagonist Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova0000N/A
Protagonist Therapeutics00703.00

Protagonist Therapeutics has a consensus target price of $38.00, indicating a potential upside of 42.75%. Given Protagonist Therapeutics' higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Sernova.

Institutional and Insider Ownership

97.5% of Protagonist Therapeutics shares are held by institutional investors. 14.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Sernova has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sernova and Protagonist Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A$-2,990,000.00N/AN/A
Protagonist Therapeutics$230,000.005,085.46$-77,190,000.00($2.98)-8.93

Sernova has higher earnings, but lower revenue than Protagonist Therapeutics.

Profitability

This table compares Sernova and Protagonist Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SernovaN/A-195.56%-151.94%
Protagonist Therapeutics-252.03%-54.00%-35.38%

Summary

Protagonist Therapeutics beats Sernova on 9 of the 11 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Sernova's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.35
SernovaN/AN/A$-2,990,000.00N/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Y-mAbs Therapeutics and Sernova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Sernova0000N/A

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, indicating a potential upside of 122.68%. Given Y-mAbs Therapeutics' higher probable upside, research analysts plainly believe Y-mAbs Therapeutics is more favorable than Sernova.

Risk & Volatility

Y-mAbs Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Y-mAbs Therapeutics and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
SernovaN/A-195.56%-151.94%

Summary

Y-mAbs Therapeutics beats Sernova on 7 of the 9 factors compared between the two stocks.

Sernova (OTCMKTS:SEOVF) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares Sernova and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SernovaN/A-195.56%-151.94%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Sernova and Phathom Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/A$-2,990,000.00N/AN/A
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.53

Volatility and Risk

Sernova has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sernova and Phathom Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova0000N/A
Phathom Pharmaceuticals10402.60

Phathom Pharmaceuticals has a consensus target price of $53.00, indicating a potential upside of 49.72%. Given Phathom Pharmaceuticals' higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Sernova.

Summary

Phathom Pharmaceuticals beats Sernova on 7 of the 9 factors compared between the two stocks.

Kronos Bio (NASDAQ:KRON) and Sernova (OTCMKTS:SEOVF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Kronos Bio and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kronos BioN/AN/AN/A
SernovaN/A-195.56%-151.94%

Valuation & Earnings

This table compares Kronos Bio and Sernova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/AN/AN/AN/A
SernovaN/AN/A$-2,990,000.00N/AN/A

Analyst Ratings

This is a summary of current ratings and target prices for Kronos Bio and Sernova, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kronos Bio00403.00
Sernova0000N/A

Kronos Bio currently has a consensus price target of $43.6667, indicating a potential upside of 117.46%. Given Kronos Bio's higher possible upside, equities analysts clearly believe Kronos Bio is more favorable than Sernova.

Summary

Kronos Bio beats Sernova on 4 of the 4 factors compared between the two stocks.


Sernova Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$14.78+3.1%$1.16 billion$4.23 million-8.26
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.01+0.1%$1.16 billion$59.70 million-190.10
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.62+2.0%$1.15 billion$230,000.00-12.38
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.11+2.5%$1.14 billionN/A-8.79Increase in Short Interest
News Coverage
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$35.40+2.3%$1.13 billionN/A-2.53
Kronos Bio logo
KRON
Kronos Bio
1.7$20.08+0.1%$1.13 billionN/A0.00
Omeros logo
OMER
Omeros
1.4$18.55+2.5%$1.12 billion$111.81 million-7.79News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$31.16+2.0%$1.12 billionN/A-17.31
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$15.90+0.4%$1.10 billion$42.12 million-11.78
NKTX
Nkarta
1.8$31.25+4.0%$1.07 billionN/A0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.10+3.9%$1.06 billionN/A-6.79Upcoming Earnings
Zogenix logo
ZGNX
Zogenix
1.7$18.80+0.6%$1.05 billion$3.65 million-1.98
MannKind logo
MNKD
MannKind
1.4$4.23+1.7%$1.04 billion$63.04 million-20.14Increase in Short Interest
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.60+0.3%$1.03 billionN/A-7.97
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.97+2.3%$1.03 billionN/A0.00News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.38+0.6%$1.02 billionN/A-6.70Increase in Short Interest
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$28.18+0.9%$1.02 billion$57.05 million0.00Analyst Report
News Coverage
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.85+0.7%$1.01 billion$800.40 million23.44
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.94+21.8%$1.01 billion$35.22 million-6.53Gap Up
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$51.10+2.4%$1.01 billion$122.47 million-28.08
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.23+4.3%$992.09 million$120,000.00-3.42Analyst Report
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$36.64+0.7%$970.00 million$20.79 million-12.63
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.67+0.4%$954.57 millionN/A-7.82
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.87+2.8%$941.57 millionN/A-12.84
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$13.42+44.4%$934.81 million$1.52 million-7.14Increase in Short Interest
News Coverage
Gap Down
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.33+3.2%$920.14 millionN/A0.00
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.55+0.7%$902.28 million$227.19 million45.97Analyst Downgrade
Prothena logo
PRTA
Prothena
2.3$22.53+5.5%$901.34 million$810,000.00-8.80
Radius Health logo
RDUS
Radius Health
1.3$19.13+1.2%$886.30 million$173.32 million-7.84
Ardelyx logo
ARDX
Ardelyx
1.6$8.07+9.2%$868.88 million$5.28 million-7.99Increase in Short Interest
Vectura Group logo
VEGPF
Vectura Group
0.5$1.43+0.0%$864.09 million$227.68 million-35.75Analyst Downgrade
Affimed logo
AFMD
Affimed
1.6$8.96+7.4%$849.70 million$23.96 million-15.19Earnings Announcement
Analyst Report
Analyst Revision
Merus logo
MRUS
Merus
1.8$22.06+0.2%$842.61 million$31.13 million-7.19
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.17+2.9%$840.11 millionN/A-22.38
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.14+0.9%$825.04 million$322.36 million122.43
ADVANZ PHARMA logo
CXRXF
ADVANZ PHARMA
0.5$16.84+0.3%$823.92 million$508.32 million-8.06
Annexon logo
ANNX
Annexon
1.9$21.78+1.2%$821.16 millionN/A0.00
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$22.81+2.0%$818.85 million$296.70 million46.55Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.04+2.6%$814.84 millionN/A-10.10News Coverage
Epizyme logo
EPZM
Epizyme
1.8$7.74+0.1%$786.80 million$23.80 million-3.47Analyst Report
News Coverage
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.02+0.1%$772.43 millionN/A0.00Increase in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.54+2.4%$751.39 million$148.36 million-7.15
Humanigen logo
HGEN
Humanigen
1.7$13.54+2.6%$742.87 millionN/A0.00Analyst Report
News Coverage
BLUSF
BELLUS Health
0.5$4.61+0.7%$733.53 million$30,000.000.00High Trading Volume
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.55+6.8%$709.73 million$6.83 million-19.12
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88+0.8%$698.67 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.44+2.2%$692.81 million$40.89 million-3.26News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17+0.9%$675.74 million$150,000.00-4.53News Coverage
EMIS
Emisphere Technologies
0.9$7.81+0.0%$673.08 millionN/A0.00
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.02+3.4%$671.97 million$19.56 million-18.72
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.